Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000175455 | SCV000226937 | pathogenic | not provided | 2015-04-17 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000648152 | SCV000769966 | likely pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2K; Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B1; Walker-Warburg congenital muscular dystrophy | 2024-11-11 | criteria provided, single submitter | clinical testing | This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 653 of the POMT1 protein (p.Pro653Leu). This variant is present in population databases (rs149682171, gnomAD 0.01%). This missense change has been observed in individual(s) with POMT1-related conditions (PMID: 24491487, 31311558, 34925456). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 194962). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed for this missense variant. However, the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on POMT1 protein function. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |
Revvity Omics, |
RCV000175455 | SCV002019492 | pathogenic | not provided | 2023-03-08 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV004567380 | SCV005052411 | likely pathogenic | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A1 | 2024-03-21 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV005049457 | SCV005674912 | likely pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2K; Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A1; Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B1 | 2024-04-22 | criteria provided, single submitter | clinical testing |